Does the media favor IMVT or HRMY?

In the previous week, Harmony Biosciences had 10 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Harmony Biosciences and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.00 beat Harmony Biosciences' score of 0.99 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PCVX or HRMY?

In the previous week, Vaxcyte had 1 more articles in the media than Harmony Biosciences. MarketBeat recorded 15 mentions for Vaxcyte and 14 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 0.99 beat Vaxcyte's score of 0.99 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HRMY or IBRX?

In the previous week, Harmony Biosciences and Harmony Biosciences both had 14 articles in the media. Harmony Biosciences' average media sentiment score of 0.99 beat ImmunityBio's score of 0.57 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 6 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HRMY or RYTM?

In the previous week, Harmony Biosciences had 1 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 14 mentions for Harmony Biosciences and 13 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.11 beat Harmony Biosciences' score of 0.99 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor HRMY or MIRM?

In the previous week, Harmony Biosciences had 5 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 14 mentions for Harmony Biosciences and 9 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.34 beat Harmony Biosciences' score of 0.99 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Harmony Biosciences (HRMY) Competitors

$38.18 +2.59 (+7.26%)

As of 12:31 PM Eastern

Compare

HRMY vs. IMVT, PCVX, IBRX, RYTM, and MIRM

Should you buy Harmony Biosciences stock or one of its competitors? MarketBeat compares Harmony Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Harmony Biosciences include Immunovant (IMVT), Vaxcyte (PCVX), ImmunityBio (IBRX), Rhythm Pharmaceuticals (RYTM), and Mirum Pharmaceuticals (MIRM).

How does Harmony Biosciences compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Harmony Biosciences (NASDAQ:HRMY) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Harmony Biosciences has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Harmony Biosciences	$868.45M	2.55	$158.69M	$2.48	15.40

Immunovant currently has a consensus price target of $42.11, indicating a potential upside of 7.16%. Harmony Biosciences has a consensus price target of $42.63, indicating a potential upside of 11.63%. Given Harmony Biosciences' higher probable upside, analysts clearly believe Harmony Biosciences is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Harmony Biosciences had 10 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Harmony Biosciences and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.00 beat Harmony Biosciences' score of 0.99 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harmony Biosciences	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences has a net margin of 16.20% compared to Immunovant's net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Harmony Biosciences	16.20%	17.19%	11.99%

Immunovant has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Summary

Harmony Biosciences beats Immunovant on 13 of the 15 factors compared between the two stocks.

How does Harmony Biosciences compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Harmony Biosciences (NASDAQ:HRMY) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

In the previous week, Vaxcyte had 1 more articles in the media than Harmony Biosciences. MarketBeat recorded 15 mentions for Vaxcyte and 14 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 0.99 beat Vaxcyte's score of 0.99 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harmony Biosciences	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences has a net margin of 16.20% compared to Vaxcyte's net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Harmony Biosciences	16.20%	17.19%	11.99%

Harmony Biosciences has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Harmony Biosciences	$868.45M	2.55	$158.69M	$2.48	15.40

Vaxcyte has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Vaxcyte presently has a consensus target price of $86.00, suggesting a potential upside of 56.47%. Harmony Biosciences has a consensus target price of $42.63, suggesting a potential upside of 11.63%. Given Vaxcyte's higher probable upside, equities analysts plainly believe Vaxcyte is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Harmony Biosciences beats Vaxcyte on 11 of the 16 factors compared between the two stocks.

How does Harmony Biosciences compare to ImmunityBio?

Harmony Biosciences (NASDAQ:HRMY) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Harmony Biosciences currently has a consensus price target of $42.63, suggesting a potential upside of 11.63%. ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 105.05%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by insiders. Comparatively, 66.1% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Harmony Biosciences and Harmony Biosciences both had 14 articles in the media. Harmony Biosciences' average media sentiment score of 0.99 beat ImmunityBio's score of 0.57 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	6 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market.

Harmony Biosciences has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.55	$158.69M	$2.48	15.40
ImmunityBio	$113.29M	64.02	-$351.40M	-$0.85	N/A

Harmony Biosciences has a net margin of 16.20% compared to ImmunityBio's net margin of -606.15%. Harmony Biosciences' return on equity of 17.19% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
ImmunityBio	-606.15%	N/A	-59.53%

Summary

Harmony Biosciences beats ImmunityBio on 11 of the 16 factors compared between the two stocks.

How does Harmony Biosciences compare to Rhythm Pharmaceuticals?

Harmony Biosciences (NASDAQ:HRMY) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

86.2% of Harmony Biosciences shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Harmony Biosciences has a net margin of 16.20% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Harmony Biosciences' return on equity of 17.19% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Harmony Biosciences has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.55	$158.69M	$2.48	15.40
Rhythm Pharmaceuticals	$189.76M	37.73	-$196.54M	-$3.13	N/A

Harmony Biosciences has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

Harmony Biosciences presently has a consensus price target of $42.63, indicating a potential upside of 11.63%. Rhythm Pharmaceuticals has a consensus price target of $138.73, indicating a potential upside of 32.80%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Harmony Biosciences had 1 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 14 mentions for Harmony Biosciences and 13 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.11 beat Harmony Biosciences' score of 0.99 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Harmony Biosciences beats Rhythm Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Harmony Biosciences compare to Mirum Pharmaceuticals?

Harmony Biosciences (NASDAQ:HRMY) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Harmony Biosciences currently has a consensus price target of $42.63, indicating a potential upside of 11.63%. Mirum Pharmaceuticals has a consensus price target of $143.40, indicating a potential upside of 37.40%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

86.2% of Harmony Biosciences shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Harmony Biosciences has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.55	$158.69M	$2.48	15.40
Mirum Pharmaceuticals	$521.31M	12.21	-$23.36M	-$13.61	N/A

In the previous week, Harmony Biosciences had 5 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 14 mentions for Harmony Biosciences and 9 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.34 beat Harmony Biosciences' score of 0.99 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

Harmony Biosciences has a net margin of 16.20% compared to Mirum Pharmaceuticals' net margin of -140.24%. Harmony Biosciences' return on equity of 17.19% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Summary

Harmony Biosciences beats Mirum Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Harmony Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HRMY vs. The Competition

Export

Metric	Harmony Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.21B	$11.50B	$6.81B	$12.94B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	15.40	791.51	279.92	25.45
Price / Sales	2.55	943.66	647.84	115.11
Price / Cash	11.08	14.82	28.64	34.82
Price / Book	2.53	10.39	11.11	6.33
Net Income	$158.69M	$2.80B	$3.48B	$347.60M
7 Day Performance	6.75%	1.61%	2.04%	2.78%
1 Month Performance	2.48%	-3.16%	-3.16%	-2.36%
1 Year Performance	7.44%	155.11%	63.65%	20.74%

Harmony Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HRMY Harmony Biosciences	4.0473 of 5 stars	$38.19 +7.3%	$42.63 +11.6%	+3.5%	$2.21B	$868.45M	15.40	200	News Coverage Earnings Report Gap Up
IMVT Immunovant	1.7664 of 5 stars	$40.09 +1.7%	$42.11 +5.0%	+145.1%	$8.13B	N/A	N/A	120	Positive News Upcoming Earnings
PCVX Vaxcyte	2.7974 of 5 stars	$55.50 +1.5%	$86.00 +55.0%	+62.1%	$7.89B	N/A	N/A	160	Upcoming Earnings
IBRX ImmunityBio	2.4292 of 5 stars	$6.99 -1.5%	$14.20 +103.1%	+201.7%	$7.44B	$113.29M	N/A	590	Earnings Report Gap Down
RYTM Rhythm Pharmaceuticals	3.4138 of 5 stars	$106.13 +3.9%	$138.73 +30.7%	+16.4%	$7.00B	$189.76M	N/A	140	News Coverage Positive News Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HRMY) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harmony Biosciences (HRMY) Competitors

HRMY vs. IMVT, PCVX, IBRX, RYTM, and MIRM

How does Harmony Biosciences compare to Immunovant?

Summary

How does Harmony Biosciences compare to Vaxcyte?

Summary

How does Harmony Biosciences compare to ImmunityBio?

Summary

How does Harmony Biosciences compare to Rhythm Pharmaceuticals?

Summary

How does Harmony Biosciences compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY vs. The Competition

Harmony Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harmony Biosciences (HRMY) Competitors

HRMY vs. IMVT, PCVX, IBRX, RYTM, and MIRM

How does Harmony Biosciences compare to Immunovant?

Do insiders & institutionals believe in IMVT or HRMY?

Which has higher valuation & earnings, IMVT or HRMY?

Do analysts recommend IMVT or HRMY?

Does the media favor IMVT or HRMY?

Is IMVT or HRMY more profitable?

Which has more risk & volatility, IMVT or HRMY?

Summary

How does Harmony Biosciences compare to Vaxcyte?

Does the media prefer PCVX or HRMY?

Is PCVX or HRMY more profitable?

Which has stronger earnings & valuation, PCVX or HRMY?

Which has more volatility & risk, PCVX or HRMY?

Do analysts rate PCVX or HRMY?

Do insiders & institutionals hold more shares of PCVX or HRMY?

Summary

How does Harmony Biosciences compare to ImmunityBio?

Do analysts rate HRMY or IBRX?

Do insiders & institutionals hold more shares of HRMY or IBRX?

Does the media favor HRMY or IBRX?

Which has more risk and volatility, HRMY or IBRX?

Which has better valuation and earnings, HRMY or IBRX?

Is HRMY or IBRX more profitable?

Summary

How does Harmony Biosciences compare to Rhythm Pharmaceuticals?

Do insiders and institutionals have more ownership in HRMY or RYTM?

Is HRMY or RYTM more profitable?

Which has stronger valuation & earnings, HRMY or RYTM?

Which has more risk and volatility, HRMY or RYTM?

Do analysts recommend HRMY or RYTM?

Does the media refer more to HRMY or RYTM?

Summary

How does Harmony Biosciences compare to Mirum Pharmaceuticals?

Do analysts prefer HRMY or MIRM?

Do insiders and institutionals believe in HRMY or MIRM?

Which has stronger valuation and earnings, HRMY or MIRM?

Does the media favor HRMY or MIRM?

Which has more volatility & risk, HRMY or MIRM?

Is HRMY or MIRM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY vs. The Competition

Harmony Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools